Promising Therapies for B-cell Non-Hodgkin’s Lymphoma (NHL)

Promising Therapies for B-cell Non-Hodgkin’s Lymphoma (NHL)
Unmet needs remain in B-cell NHL, which will provide opportunities for developers, including the need for predictive and prognostic biomarkers, better therapies for relapsed or refractory DLBCL, further options in FL for specific patient subsets, and therapies for MCL patients refractory to and relapsed after treatment with Imbruvica.

1 . Leading Marketed Therapies for B-cell Non-Hodgkin’s Lymphoma (NHL) 

CAR-T therapies, including the currently marketed Yescarta and Kymriah and the pipeline agent lisocabtagene maraleucel, are expected to result in significant revenues due to premium pricing and clinical benefit in heavily pre-treated patients. Their combined revenues are expected to reach around USD 2.4bn in 2027.
 
Increasing prevalence, primarily by aging populations and the approval and launch of new branded therapies: lisocabtagene maraleucel, ublituximab with umbralisib, Blincyto, tafasitamab, Venclexta, and enzastaurin will drive market growth. FDA approved currently marketed therapies are: 
  • Yescarta
  • Kymriah
  • Polivy
  • Revlimid
  • Calquence
  • Aliqopa
  • Imbruvica
B-cell Non-Hodgkin’s Lymphoma (NHL) Leading Marketed Therapies
CAR-T therapies have been highly anticipated in NHL, and they are expected to improve treatment outcomes in heavily-treated patients, an area of major unmet need. While currently only approved for the DLBCL subtype, CAR-T therapies are expected to expand into FL, MZL and MCL, and earlier lines of therapy between 2017 and 2027. 
 
 
B-Cell Non-Hodgkin’s Lymphoma (NHL): Opportunity Analysis and Forecasts to 2027

B-Cell Non-Hodgkin’s Lymphoma (NHL): Opportunity Analysis and Forecasts to 2027 report offers an overview of B-cell NHL (FL, MZL, DLBCL and MCL), including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.

It also offers an insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

 

2 . B-cell non-Hodgkin’s lymphoma (NHL) Market Forecast

The B-cell non-Hodgkin’s lymphoma (NHL) market is expected to grow from $5.7bn in 2017 to USD 9.2bn by 2027 across the seven major markets (7MM*) at a compound annual growth rate (CAGR) of 4.9%. The main driver of the growth will be the rise of chimeric antigen receptor (CAR) T cell therapies.
 
b-cell nhl market forecast
The growth of the B-cell NHL market will be tempered by the patent expiry of leading brands, including Rituxan, Treanda, Gazyva, Revlimid, Imbruvica, Zydelig, and Velcade, and subsequent biosimilar/generic erosion. A major barrier for market growth in B-cell NHL, however, will be the increased use of biosimilars and generics, in particular, biosimilar rituximab. The branded Rituxan alone brought in around USD 2.5bn in the US in 2018.
 
 

Related Biotech Industry Articles

1. RNA-Targeted Small Molecules: Emerging Discoveries are Catching the Eye of Investors

2. Amgen and Roche to Lead Global Bispecific Antibodies Market

3. Top 10 Oncology Pharma Companies in the World

 

Contact Us for Custom Market Research Solutions

 

MarketResearchReports.com Newsletter Subscription

About The Author

sudeep's picture
Sudeep Chakravarty

Feature your company here

Clients Who Trust Us

Market Research Reports Inc. Customers

Need tailor made market research solution? We can help you with that too.

About Us

At Market Research Reports, Inc. we aim to make it easier for decision makers to find relevant information and locate right market research reports which can save their time and assist in what they do best, i.e. take time-critical decisions.

We work with our associate Global market research firms who are known leaders in their respective domains to obtain right market research solution for our customer’s needs, be it custom research or syndicated research reports.

Contact Us

Market Research Reports, Inc
16192 Coastal Hwy
Lewes
, DE 19958, USA

USA: +1-302-703-9904

India: +91-8762746600

marketresearchreports

info@marketresearchreports.com

User login

Stay Connected